BB Biotech AG (BB.XMIL) Quality Score

Quality25

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Growth

Cash Flow Growth

100/100

14.2%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution

0/100

6.2%

Heavy dilution above 5%

Capital Structure

100/100

-CHF 98M

Net cash position, no leverage concern

2022

CHF 2M

CHF 363M

2023

CHF 501000

CHF 305M

2024

CHF 458000

CHF 118M

2025

CHF 98M

CHF 0

TTM

CHF 98M

CHF 0

Customize WeightsPremiumAdjust metric weights to match your investment style.Upgrade

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BB.XMIL

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.